Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.60 |
| ▸ | TYMP | P19971 | 4/20 | 0.50 |
| ▸ | PYGM | P11217 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8163247 | 1.00 | TK2 (0.60) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL25407084 | 0.92 | TK2 (0.53) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL767907 | 0.91 | TK2 (0.59) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL774127 | 0.91 | TK2 (0.59) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL773378 | 0.91 | TK2 (0.59) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL9908678 | 0.91 | TK2 (0.59) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL9908677 | 0.91 | TK2 (0.59) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL767995 | 0.91 | TK2 (0.59) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL774129 | 0.90 | TK2 (0.63) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL4951033 | 0.90 | TK2 (0.61) | TK2TYMPPYGMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1615 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022089486-A1 | SIRNA FOR INHIBITING PCSK9 GENE EXPRESSION AND MODIFIER THEREOF AND USE THEREOF | 江苏柯菲平医药股份有限公司 | 2022-05-05 | — | — | WO | claimed |
| WO-2022088342-A1 | SIRNA TARGETING FOXP3 GENE AND MODIFICATION METHOD THEREFOR | 苏州吉玛基因股份有限公司 | 2022-05-05 | — | — | WO | claimed |
| US-9290760-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | claimed |
| US-20130317080-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | claimed |
| EP-4744669-A2 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026102027-A2 | COMPOSITIONS TARGETING AU-RICH ELEMENTS OF FGF21 GENE AND GDF15 GENE AND METHODS OF USE THEREOF | POSEIDA THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4727929-A2 | 5'-MODIFIED MONOMERS, OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | Alnylam Pharmaceuticals, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729120-A2 | METHODS AND COMPOSITIONS FOR TREATING A BLEEDING EVENT IN A SUBJECT HAVING HEMOPHILIA | Genzyme Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12600965-B2 | Modified double stranded oligonucleotide | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260098263-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4720288-A2 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING FL1-1 EXPRESSION | Editas Medicine, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-5789573-A | OLIGOMERS WHICH HYBRIDIZE WITH ENDCAPPED TARGET RNA TRANSCRIPT | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| WO-1998029124-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| EP-0813539-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1997046570-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997045437-A1 | COMPOSITIONS AND METHODS FOR ANTISENSE INHIBITION OF PROTEIN TRANSLATION | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997030067-A1 | SUGAR-MODIFIED GAPPED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997029780-A1 | METHOXYETHOXY OLIGONUCLEOTIDES FOR MODULATION OF PROTEIN KINASE C EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996027606-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600965-B2 | Modified double stranded oligonucleotide | NSUN2, EIF2AK2, ADAR | TK2 270/4885TYMP 597/4885PYGM 2297/4885 |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | RNASEL, NSUN2, ADAR | TK2 454/4885TYMP 117/4885PYGM 1475/4885 |
| US-20260098263-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | NSUN2, ADAR, RNGTT | TK2 459/4885TYMP 415/4885PYGM 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.